HC Wainwright Reiterates “Buy” Rating for Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $37.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 325.29% from the stock’s current price.

Pharming Group Stock Up 4.8 %

Shares of NASDAQ:PHAR opened at $8.70 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.39 and a quick ratio of 2.65. The stock has a market cap of $590.12 million, a price-to-earnings ratio of -45.79 and a beta of 0.15. The company has a 50 day moving average of $8.05 and a 200-day moving average of $8.55. Pharming Group has a one year low of $6.65 and a one year high of $13.20.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The business had revenue of $74.09 million for the quarter, compared to the consensus estimate of $71.95 million. During the same quarter in the previous year, the firm posted $0.02 EPS. On average, sell-side analysts forecast that Pharming Group will post -0.15 earnings per share for the current year.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in Pharming Group (NASDAQ:PHAR) by 32.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent filing with the SEC. 0.03% of the stock is currently owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.